Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis: A Multicenter, Open-Label, Randomized Controlled Study

NCT07796516 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT07796516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07796516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis: A Multicenter, Open-Label, Randomized Controlled Study
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
September 1, 2026
Completion date
June 30, 2028
Enrollment
420 (estimated)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

difficult-to-treat rheumatoid arthritis, rheumatoid arthritis